Our previous serological analysis of recombinant tumor cDNA expression libraries (SEREX) analysis of AML patient sera, identified SSX2IP and PASD1, as well as SSX2IP’s interacting partner, SSX2, as potential targets for the immunotherapy of myeloid leukemia [27]. The gene discussed is SSX2IP; the disease is neoplasm.